2021

Zajdel P., Grychowska K., Mogilski Sz., Kurczab R., Satała G., Bugno R., Kos T., Gołębiowska J., Malikowska-Racia N., Nikiforuk A., Chaumont-Dubel S., Bantreil X., Pawłowski M., Martinez J., Subra G., Lamaty F., Marin P., Bojarski A., Popik P. Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties. J. Med. Chem. 2021

Drop M., Jacquot F., Canale V.,  Chaumont Dubel S., Walczak M., Satała G., Nosalska K.,  Umuhire Mahoro G., Słoczyńska K., Piska K., Lamoine S., Pękala E., Masurier N., Bojarski A., Pawłowski M., Martinez J., Subra G., Bantreil X., Zajdel P. Neuropathic pain-alleviating activity of novel 5-HT receptor inverse agonists derived from 2-aryl-1H-pyrrole-3-carboxamide₆. Bioorg. Chem. 2021, 115, 105218 

Salerno V., Vanella L., Sorrenti V., Consoli V., Ciaffaglione V.,  Fallica A. N.,  Canale V., Zajdel P., Pignatello R., Intagliata S. Novel mutual prodrug of 5-fluorouracil and heme oxygenase-1 inhibitor (5-FU/HO-1 hybrid): design and preliminary in vitro evaluation. J. Enzym Inhib. Med. Chem. 2021, 36, 1378-1386. 

Canale V., Kotańska M., Dziubina A., Stefaniak M., Siwek A., Starowicz G., Marciniec K., Kasza P., Satała G., Duszyńska B., Bantreil X., Lamaty F., Bednarski M., Sapa J., Zajdel P.  Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual α2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties. Molecules. 2021, 26, 3828.     

Drop M., Canale V., Chaumont S., Kurczab R., Satała G., Bantreil X., Walczak M., Koczurkiewicz P., Latacz G., Gwizdak A., Krawczyk M., Gołębiowska J., Grychowska K., Bojarski A., Nikiforuk A., Subra G., Martinez J., Pawłowski M., Popik P., Marin P., Lamaty F., Zajdel P. 2‑Phenyl‑1H‑pyrrole-3-carboxamide as a New Scaffold for Developing 5‑HT6 Receptor Inverse Agonists with Cognition Enhancing Enhancing Activity. ACS Chem. Neurosci. 2021, 12, 7, 1228-1240 

Vanda D., Canale V., Chaumont-Dubiel S., Kurczab R., Satała G., Koczurkiewicz-Adamczyk P., Krawczyk M., Pietruś W., Blicharz K., Pękala E., Bojarski A., Popik P., Marin P., Soural M., Zajdel P. Imidazopyridine-Based 5-HT₆ Receptor Neutral Antagonists: Impact of N¹-Benzyl and N¹-Phenylsulfonyl Fragments on Different Receptor Conformational States. J. Med. Chem. 2021, 64, 1180-1196

Ručilová V., Świerczek A., Vanda D., Funk P., Lemrová B., Gawalska A., Bucki A., Nowak B., Zadrożna M., Pociecha K., Soural M., Wyska E., Pawłowski M., Chłoń-Rzepa G., Zajdel P. New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases. Eur. J. Med. Chem. 2021, 209, 112854

2020

Canale V., Grychowska K., Kurczab R., Ryng M., Keeri Abdul R., Satała G., Olejarz-Maciej A., Koczurkiewicz P., Drop M., Blicharz K., Piska K., Pękala E., Janiszewska P., Krawczyk M., Walczak M., Chaumont-Dubel S., Bojarski A., Marin P., Popik P., Zajdel P. A dual-acting 5-HT₆ receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties. Eur. J. Med. Chem., 2020, 208, 112765                                                                                               

Berthoux C., Hamieh Al M., Rogliardo A., Doucet Emilie L., Coudert C., Ango F., Grychowska K., Chaumont-Dubel S., Zajdel P., Maldonado R., Bockaert J., Marin P, Becamel C. Early 5-HT6 receptor blockade prevents symptom onset in a model of adolescent cannabis abuse. EMBO Molecular Medicine 2020, 12, e10605

Martin Pierre-Y., Doly S., Hamieh Al M., Chapuy E., Canale V., Drop M., Chaumont-Dubel S., Bantreil X., Lamaty F., Bojarski A., Zajdel P., Eschalier A., Marin P., Courteix C. mTOR activation by constitutively active serotonin6 receptors as new paradigm in neuropathic pain and its treatment. Progr. Neurobiol. 2020, 193, 101846

Canale V., Frisi V., Bantreil X., Lamaty F., Zajdel P. Sustainable Synthesis of a Potent and Selective 5-HT₇ Receptor Antagonist Using a Mechanochemical Approach J. Org. Chem. 2020, 85, 16, 10958–10965

Staroń J., Kurczab R., Warszycki D., Satała G., Krawczyk M., Bugno R., Lenda T., Popik P., Hogendorf A S., Hogendorf A., Dubiel K., Matłoka M., Moszczyński – Pętkowski R., Pieczykolan J., Wieczorek M., Zajdel P., Bojarski A J. Virtual screening-driven discovery of dual 5-HT₆/5-HT_2A receptor ligands with pro-cognitive properties. Eur. J. Med. Chem, 2020, 185, 111857

Szafrański P., Trybula M.E., Kasza P., Cegła M.  Following the oxidation state of organosulfur compounds with NMR : Experimental data versus DFT calculations and database-powered NMR prediction. J. Mol. Struct, 2020, 1202, 127346

2019

Kasza P., Trybula M.E., Baradziej K., Kepczynski M., Szafrański P.W., Cegła M.T. Fluorescent triazolyl spirooxazolidines: Synthesis and NMR stereochemical studies. J. Mol. Struc., 2019, 1183, 157-167

2017

Smaga I., Zaniewska M., Gawliński D., Faron-Górecka A., Szafrański P., Cegła M., Filip M. Changes in the cannabinoids receptors in rats following treatment with antidepressants . Neurotoxicology, 2017, 63, 13-20

Dąbrowska M., Starek M., Komsta Ł., Szafrański P., Stasiewicz-Urban A., Opoka W. Assessment of the chromatographic lipophilicity of eight cephalosporins on different stationary phases. European Journal of Pharmaceutical Sciences, 2017, 101, 115124

2016

Tarsa M., Starek M., Zuchowski G., Stasiewicz-Urban A., Cegła M. Kinetics of Hydrolysis ofN-Methyl-2,4-dithiophenobarbital. Aust. J. Chem., 2016, 69, 89–97

2015

Szafrański P.W., Kasza P., Cegła M. A new water-soluble ligand for efficient copper-catalyzed Huisgen cycyloaddition of aliphatic azides and alkynes. Tetrahedron Letters, 2015, 56, 6244-6247

Szafrański P.W., Kasza P., Kępczyński M., Cegła T.M. Fluorescent 1,2,3-triazole derivative of 3’-deoxy-3-azidothymidine: Synthesis and absorbtion/emission spectra. Heterocycl.Commun., 2015, 21, 263-267

Waszkielewicz A., Gunia-Krzyzak A., Cegla M., Marona H. Synthesis and evaluation of anticonvulsant activity of n-(2,5-dimethylphenoxy)- and n-[(2,3,5-trimethylphenoxy)alkyl]aminoalkanols. Acta Poloniae Pharmaceutica, 2015, 72, 89-99